PubMed Health⌕ Search

Biomedical subjects

T Yamagami

Publications and source records attributed to T Yamagami.

At least 217 records · Page 12Linked to original sources
PubMed1978

Changes of behavior, fear and thought in the treatment by response prevention--a case study of obsessive compulsive disorder.

A 15-year-old boy with compulsive hand washing and fear of contamination was treated by response prevention. Each series of the response prevention was experimentally divided into four periods: total response prevention, partial response prevention, free hand washing under noticed observation, and free from prevention and free from observation periods. After nine repeats of the series he became free of the symptoms. Temporal increase of fear and appearance of "freezing" phenomenon were observed in the total response prevention periods. Besides decrease in fear and hand washing, there was observed a change of his thought on symptoms with progress of the treatment. Based on these observations and results, the mechanism of treatment of response prevention was discussed.

Adolescent↗
PubMed1976

A clinical study of the effect of coenzyme Q on congestive heart failure.

Expecting activation of myocardial energy liberation, coenzyme Q was applied as a treatment to 55 patients suffering from congestive heart failure. Daily doses of 50 to 100 mg of coenzyme Q7 were injected intravenously in 21 cases for 3 to 35 days. Daily doses of 60 mg of coenzyme Q7 were administered perorally in 17 cases for 14 to 196 days. Daily doses of 30 mg of coenzyme Q10 were administered perorally in 17 cases for 7 to 182 days. Clinical effects were evaluated within 4 weeks by the criteria using a scoring method of severity of congestive heart failure which was devised by the authors. In summary a certain effect was found in 20 cases and a mild effect was observed in 29 cases. No significant changes were observed in heart rate and blood pressure. Exanthema appeared in 2 patients of the group of coenzyme Q7 intravenous injection. In conclusion the therapeutic effect of coenzyme Q was thought to be mild but stable in supplement to digitalis therapy in cases of congestive heart failure.

Administration, Oral↗
PubMed1976

Bioenergetics in clinical medicine. VIII. Adminstration of coenzyme Q10 to patients with essential hypertension.

Coenzyme Q10 has been administered to five patients having essential hypertension and deficiencies of activity of succinate dehydrogenase-co-enzyme Q10 reductase in leucocyte preparations ranging from 20-40%. For a 74-year old male, the systolic pressure was reduced (p less than 0.001), the diastolic pressure was reduced (p less than 0.05), the specific activity of the coenzyme Q10-enzyme was increased (p less than 0.001), and the deficiency of coenzyme Q10 activity was negated (p less than 0.01). Four patients receiving CoQ10 for 3-5 months showed reductions (p less than 0.05 to p less than 0.001) of diastolic pressure, and 3 of these 4 showed reductions (p less than 0.05 to p less than 0.01) of diastolic pressure. Initial deficiencies of enzyme activity were reduced (p less than 0.01 to 0.05) in two patients. Three other patients did not show the high level of deficiency on treatment as initially observed. These effects of CoQ10 on the reduction of systolic and diastolic blood pressures, increase in CoQ10-enzyme activity, and reduction of CoQ10-deficiency are presumably due to improved bioenergetics through correction of a deficiency of coenzyme Q10.

Adult↗
PubMed1975

Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension.

The specific activities (S.A.) of the succinate dehydrogenase-coenzyme Q10 (CoQ10) reductase of a control group of 65 Japanese adults and 59 patients having essential hypertension were determined. The mean S.A. of the hypertensive group was significantly lower (p less than 0.001) and the mean % deficiency of enzyme activity was significantly higher (p less than 0.001) than the values for the control group. These data on Japanese in Osaka agree with data on Americans in Dallas. Some patients showed no CoQ10-deficiency, and others showed definite deficiencies. Emphasizing the CoQ10-enzyme for patient selection, CoQ10 was administered to hypertensive patients. Four individuals showed significant but partial reductions of blood pressure. Monitoring the CoQ10-enzyme before, during, and after administration of CoQ10 indicated responses. The maintenance of high blood pressure could be primarily due to contraction of the arterial wall. Contraction or relaxation of an arterial wall is dependent upon bioenergetics, which also provide the energy for biosynthesis of angiotensin II, renin, aldosterone, and the energy for sodium and potassium transport. A clinical benefit from administration of CoQ10 to patients with essential hypertension could be based upon correcting a deficiency in bioenergetics, and point to possible combination treatments with a form of CoQ and anti-hypertensive drugs.

Adult↗
PubMed1975

Energy metabolism in the infarcted cardiac muscle: the interaction of contractile protein and mitochondria.

In order to investigate the behavior of the energy-converting system in the myocardium, an experimental in vitro model was developed which consisted of contractile protein (myosin B) and mitochondria (Mit) prepared from canine cardiac muscle. In this system, ATP produced in Mit from added ADP caused the superprecipitation of the myosin B (My-B). One hour after the onset of experimental myocaridal infarction in the dog, the superprecipitation was very low in the system if Mit prepared from the infarcted myocardium were used, regardless of the origin of the myosin B. The respiratory control index of Mit prepared from infarcted was lower than that from noninfarcted myocardium, but the ADP:O ratio in Mit from infarcted myocardium, was little deteriorated. The findings indicate that a transferring process of an energy source from Mit to myosin B was markedly impaired in the infarcted myocardium. They also throw light on the mechanism by which the myocardium ceases its contraction at an early stage of infarction.

Animals↗